Aravind Eye Hospital, Madurai, India: In Service for Sight, The

V. Kasturi  Rangan

Case | HBS Case Collection | April 1993 (Revised May 2009)

Aravind Eye Hospital, Madurai, India: In Service for Sight, The

Abstract

Starting as a modest 20-bed hospital, Aravind had grown into a 1,400-bed hospital complex by 1992. It had by then screened 3.65 million patients and performed 335,000 cataract surgeries, nearly 70% of them free of cost for the poorest of India's blind population. Aravind's founder, Dr. Venkataswamy, now 74 years old, had a goal to spread the Aravind model to every nook and corner of India, Asia, and Africa. The case sets the stage for developing such a plan of action.

Keywords: Developing Countries and Economies; Social Marketing; Service Delivery; Service Operations; Welfare or Wellbeing; Expansion; Health Industry; India;

Format: Print

20 pages

Educators Purchase

Citation:

Rangan, V. Kasturi. "Aravind Eye Hospital, Madurai, India: In Service for Sight, The." Harvard Business School Case 593-098, April 1993. (Revised May 2009.)

This (B) case describes the changes in the organization’s strategy from one of Building Playgrounds to Influencing Play. It describes the implementation of the strategy and the challenges it faced internally and externally. It goes on to describe how the organization under its new leader, James Siegal, further adjusted the strategy and its implementation, to navigate through the initial difficulties. The case closes with the question, what else should the organization do to help the new strategy take off?

The case asks students to formulate a strategy to respond to various competitive threats to its Pureit Water purifier, launched in 2008, targeted at millions of low-income Indian consumers who did not have access to safe drinking water. The case describes in detail the product development and launch process that required HUL, the $3.5 billion Indian subsidiary, to innovate on many different fronts. It details competitive actions since the launch to set the stage for what the company should do next.

Gilead had come up with an innovative drug for Hepatitis C, which affected 180 million people worldwide. The drug was priced at $1,000 a pill for the US market. Gilead had to decide how to price and market the pill in developing countries that bore the brunt of the disease. The company had earned accolades for its work in HIV/AIDS, where its innovative medicines now accounted for 60% of all patients on Anti-Retroviral (ARV) medicines. Much of this was accomplished through generic licensing, which brought a $10,000/year treatment regimen down to $100! Should the company replicate that strategy for Hepatitis C? If so, how would its US Healthcare customers, who were paying $84,000 per patient, react? On the other hand, Gilead had to balance the interests of its shareholders, who paid $11 billion for an acquisition that led to the new Hepatitis C drug.

Faculty & Research

Aravind Eye Hospital, Madurai, India: In Service for Sight, The

Abstract

Citation:

About the Author

More from the Author